Innate Pharma SA (NAS:IPHA)

$ 2.14 0 (0%) Market Cap: 173.23 Mil Enterprise Value: 116.50 Mil PE Ratio: 0 PB Ratio: 3.24 GF Score: 56/100

Innate Pharma SA KOL Event Transcript
Dec 12, 2023
Q3 2023 Innate Pharma SA Corporate Sales Call Transcript
Nov 14, 2023
Half Year 2023 Innate Pharma SA Earnings Call Transcript
Sep 14, 2023

$3.07 (+0.22%)

Earnings
Q1 2023 Innate Pharma SA Earnings Call Transcript
May 10, 2023

$2.94 (-3.77%)

Earnings
Q4 2022 Innate Pharma SA Earnings Call Transcript
Mar 23, 2023

$2.67 (-11.88%)

Earnings
Q3 2022 Innate Pharma SA Earnings Call Transcript
Nov 14, 2022

$2.48 (+8.30%)

Earnings
Q2 2022 Innate Pharma SA Earnings Call Transcript
Sep 15, 2022

$2.54 (+3.25%)

Earnings
Q1 2022 Innate Pharma SA Earnings Call Transcript
May 10, 2022

$2.72 (+0.56%)

Earnings
Q4 2021 Innate Pharma SA Earnings Call Transcript
Mar 24, 2022

$3.36 (-3.17%)

Earnings
Q3 2021 Innate Pharma SA Corporate Sales Call Transcript
Nov 16, 2021
Q2 2021 Innate Pharma SA Earnings Call Transcript
Sep 15, 2021

$5.58 (+2.01%)

Earnings
Innate Pharma SA To Discuss Virtual Investor Event-Call Transcript
Jun 23, 2021
Q1 2021 Innate Pharma SA Earnings Call Transcript
May 11, 2021

$4.1 (+6.22%)

Earnings
Q4 2020 Innate Pharma SA Earnings Call Transcript
Mar 18, 2021

$4.45 (-3.17%)

Earnings

Innate Pharma SA KOL Event Transcript

Dec 12, 2023 / 03:00PM GMT

Release Date Price: $2.39 (-2.05%)

Transcript

Operator

Lacutamab KOL event. (Operator Instructions) I'll now turn the conference over to Henry Wheeler, VP of Investor Relations and Communication. Please go ahead.

Henry Wheeler Innate Pharma SA;VP

IR & Communications

Thank you. Good morning, good afternoon, and welcome, everyone. Thank you for joining today's Innate KOL call on lacutamab where we look forward to sharing updates from data presented at ASH here in San Diego over the weekend. Today's presentation is available on the IR section of our website.

On slide 2, before we start, I would like to remind you that we will be making forward-looking statements regarding the financial outlook in addition to product developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.

On slide 3, on today's call, we will be joined by Dr. Sonia Quaratino, our Chief Medical Officer. And we'd also like to thank Dr. Porcu, Director, Division of Hematological Malignancies and Hematopoietic Stem Cell Transplantation,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.